Home Blog Page 9

ZOLL Announces Closing of Acquisition of Select Vyaire Ventilator Product Lines

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it successfully completed its previously announced acquisition of certain assets of Vyaire Medical’s ventilator business.

With the acquisition complete, ZOLL will immediately make available to customers the bellavista®, fabian®*, LTV®, and 3100 HFOV product lines alongside ZOLL’s other respiratory care offerings. For these acquired product lines, all ventilators and associated consumables, service parts, accessories, and service program offerings will continue to be sold where currently available. Existing Vyaire contact channels will remain available for use during a transition period. Customers can also contact ZOLL at ventsales@zoll.com.

“ZOLL’s acquisition of select Vyaire ventilator product lines is an exciting opportunity for our customers and our company,” said Jon Rennert, CEO of ZOLL. “We now have the ability to serve even more patients and customers, furthering our mission of improving patient outcomes and helping save lives.”

*Not available for sale in the U.S.

BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research

BD
The integration of Hamilton's robotics with BD's robotics-ready reagent kits can streamline workflows, reduce the potential for human error, and accelerate the pace of discovery in critical areas such as oncology and immunology.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits that will enable automation to ensure greater consistency and increased efficiency of large-scale, single-cell discovery studies.

The automated solution from the BD and Hamilton collaboration standardizes traditionally manual processes and speeds the generation of material for genetic sequencing. The solution includes the newly released BD® OMICS-One XT WTA Assay and the Hamilton® Microlab™ NGS STAR automated liquid handling platform. Because the NGS STAR is already installed in many laboratories and facilities worldwide, more researchers, processing samples across an array of genomics applications, can easily integrate the new automation-ready BD® assay into existing workflows.

In single-cell discovery studies involving genetic material, constructing preparatory material otherwise called “DNA libraries” is an essential early step. Historically, such preparations have been labor-intensive and time-consuming processes, with numerous manual steps that often lead to variability of results, compromised data quality, limited throughput, high cost and long turnaround times.

“By automating the complex library preparation process, researchers can scale their sample throughput and expect more consistent results, minimizing the variability introduced by manual procedures,” said Steve Conly, worldwide president of BD Biosciences. “This standardization is crucial for the reproducibility of experiments, which is a cornerstone of scientific research. The integration of Hamilton’s robotics with BD’s robotics-ready reagent kits can streamline workflows, reduce the potential for human error, and accelerate the pace of discovery in critical areas such as oncology and immunology.”

Matt Hamilton, CEO at Hamilton added, “Hamilton’s advanced automated solutions streamline scientific workflows, maximizing the potential of single-cell multiomics research. Our partnership with BD furthers our mission to provide innovative technologies that accelerate groundbreaking discoveries in science and medicine.”

The BD® OMICS-One XT Library Preparation Reagent Kits and Hamilton Microlab NGS STAR automated liquid handling platform and applications are commercially available globally. The robotics liquid-handling platform is available for purchase from Hamilton, and the reagent kits are available for purchase from BD representatives, or in some regions, through BD’s e-commerce portal. More information is available at bdbiosciences.com or through BD sales representatives.

Penumbra Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke

Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company’s latest computer assisted vacuum thrombectomy (CAVT™) technology, Penumbra System™ with Thunderbolt™ Aspiration Tubing, for the removal of blood clots in the brain.

“This critical milestone brings us another step closer to providing physicians with the latest technology for stroke management,” said Adam Elsesser, president and chief executive officer of Penumbra. “The THUNDER study will provide the data set needed to evaluate Penumbra’s Thunderbolt technology and I am optimistic that we are at the dawn of a new era in stroke treatment.”

Penumbra System with Thunderbolt Aspiration Tubing uses an advanced CAVT software algorithm to generate proprietary modulated aspiration, reducing friction between the clot and reperfusion catheter and facilitating a more rapid and complete removal of blood clots in the brain. Thunderbolt Aspiration Tubing has been designed for use with Penumbra ENGINE™ and RED™ reperfusion catheters.

The THUNDER study (NCT05437055) is a multi-center, single-arm study evaluating patients with acute ischemic stroke secondary to intracranial large vessel occlusion (LVO) who are eligible for mechanical thrombectomy. The primary efficacy endpoint includes revascularization of the occluded target vessel at immediate post-procedure.

Benefits of Acupuncture for Managing Pain and Reducing Anxiety

Acupuncture

Acupuncture, an ancient healing practice rooted in Traditional Chinese Medicine (TCM), has gained widespread recognition in modern healthcare for its ability to alleviate pain and manage anxiety. This holistic treatment involves inserting fine needles into specific points on the body to restore the flow of energy, or qi. Acupuncture is increasingly being used as a complementary therapy for conditions that range from chronic pain to stress and anxiety disorders. In this article, we’ll explore the scientifically backed benefits of acupuncture for pain relief and anxiety management, and how it can be an effective alternative or complement to pharmaceutical treatments.

Acupuncture for Pain Relief: How It Works

Chronic pain, such as back pain, joint pain, and migraines, can significantly impact quality of life, and while medications like Tramadol can offer relief, they come with side effects and the risk of dependency. Acupuncture provides a natural alternative that many find effective without relying solely on drugs.Acupuncture that activa

ting specific areas on the body, referred as acupoints are linked to pathways through which energy flows, and by stimulating them, acupuncture helps to balance this energy. The practice also triggers the release of endorphins, the body’s natural painkillers, and increases blood circulation to affected areas, promoting faster healing.

Scientific studies have demonstrated that acupuncture is particularly effective in managing chronic pain, reducing its intensity and frequency. It offers a natural solution that addresses the underlying cause of the pain rather than merely covering up the symptoms. For those who are used to taking medication to manage pain, acupuncture offers a drug-free option. While some people might buy Tramadol online to manage their pain, integrating acupuncture into their treatment plan can reduce their reliance on pharmaceuticals over time.

Managing Anxiety with Acupuncture

In addition to physical pain relief, acupuncture has proven benefits for mental health, particularly in managing anxiety. Anxiety disorders affect millions of people worldwide and can lead to overwhelming feelings of fear, dread, and restlessness. Medications like Xanax are often prescribed to manage anxiety symptoms, but they may not be the right fit for everyone due to potential side effects or dependency concerns.

Acupuncture provides a holistic solution to anxiety by addressing the mind-body connection. It promotes relaxation by regulating the body’s nervous system, specifically by stimulating the parasympathetic nervous system, which is responsible for inducing a calm and restful state. This practice also helps to regulate the body’s stress hormones, like cortisol, leading to a reduction in anxious feelings.

For people who prefer to manage their anxiety without relying solely on medication, acupuncture offers a viable alternative. It works by balancing the body’s energy and improving emotional well-being over time. Many patients report feeling more centered, calm, and focused after acupuncture treatments, with long-term improvements in their mental health.

Acupuncture as a Complementary Therapy

While acupuncture can be a standalone treatment, it also works effectively as a complementary therapy alongside conventional medicine. For example, people who take Xanax for anxiety or choose to buy Tramadol online for pain relief can benefit from incorporating acupuncture into their treatment plans. This combination may enhance the overall effectiveness of their treatment, as acupuncture helps the body heal itself and improves its response to medication.

Additionally, acupuncture has very few side effects when performed by a licensed practitioner. Unlike pharmaceuticals, which can lead to addiction or negative interactions with other medications, acupuncture is generally safe and well-tolerated, making it a great option for those seeking a natural treatment for pain and anxiety.

What to Expect During an Acupuncture Session

If you’re new to acupuncture, you might be wondering what to expect during a session. Typically, an acupuncturist will begin by discussing your health concerns and medical history to understand your specific needs. After this consultation, you’ll lie comfortably on a treatment table while the practitioner inserts thin, sterile needles into acupoints on your body.

The sensation of the needles is often described as a mild tingling or dull ache, but it’s generally not painful. Many people find acupuncture sessions to be deeply calming and rejuvenating, even falling asleep during treatment.

After a series of treatments, patients often notice significant improvements in their pain levels and anxiety symptoms. For those looking for a holistic and sustainable approach to their health, acupuncture offers a pathway to healing without the need for long-term medication dependency.

A Holistic Approach to Pain and Anxiety

Acupuncture is an effective and natural treatment option for managing both physical pain and mental health challenges like anxiety. It offers a holistic approach that addresses the root cause of these conditions, allowing patients to heal from the inside out. For those who rely on medications like Xanax or buy Tramadol online for pain relief, acupuncture presents a complementary solution that can enhance the effectiveness of their treatment and potentially reduce the need for pharmaceutical intervention.

By integrating acupuncture into your wellness routine, you can experience a greater sense of balance, reduced pain, and improved mental clarity, offering a more sustainable approach to health and well-being. Whether you’re struggling with chronic pain or seeking relief from anxiety, acupuncture may be the holistic therapy you’ve been looking for.

 

TriCelX, Inc. Announces Opening of Its Flagship Clinic at The Baylor Scott & White Sports Therapy & Research Center at The Star in Frisco, Texas

TriCelX, Inc., (“TriCelX”) a translational leader delivering evidence-based, cost-effective options to alleviate pain as well as to improve aesthetics and physical performance, today announced the opening of its flagship clinic at The Baylor Scott & White Sports Therapy & Research Center at The Star in Frisco, Texas. The clinic was designed and constructed to include an ISO Level 7 (FED 209E class 10,000 classification) cleanroom and is complete with two procedure rooms, each connecting independently to the cleanroom.

Under the company’s LumineX brand, surgeons provide patients with a portfolio of state-of-the-art aesthetic procedures, including futuristic body contouring, non-surgical facial refinement, skin rejuvenation and skin tightening procedures. “I’m excited to have been part of this revolution in aesthetics — moving away from a general surgical world — into a technology-based world, which affords patients with natural options — all without having to go under the knife,” said Dr. Jack Zamora, MD, Chief of Bio-Aesthetics and the creator of the J-Plazty® technique, a minimally-invasive procedure that uses Renuvion® plasma energy sub-dermally to instantly tighten and rejuvenate skin anywhere on the face and body without large incisions, downtime, or the complications of traditional surgery.

Dr. Kristen Aliano Messina, MD Chief of Plastic Surgery & Aesthetics, continued: “Our goal is to transform the field of aesthetics by blending science, technology and art. We aim to translate cutting-edge science and MedTech into evidence-based, personalized solutions to optimize patient outcomes. For example, our XSCULPT™ procedure is a next-generation body sculpting protocol incorporating three state-of-the-art FDA approved technologies:

  • a highly specialized ultrasound technology, which gently breaks down fat cells in the body using ultrasonic sound waves;
  • high-frequency, gentle vibration technology, which uses kinetic energy to further break down and remove the cells with a gentle suction process — allowing undamaged fat cells to be available for fat transfer to other parts of the body;
  • a minimally invasive treatment combining helium gas and radiofrequency energy to create a plasma specially equipped to correct sagging skin and restore a more youthful and natural appearance;
  • the latest in triphasic radiofrequency technology with Attiva for in office procedures.

Under the leadership of double-board-certified Dr. Ryan Hagens, MD, Chief of Musculoskeletal and Regenerative Medicine, OrthodynamiX translates cutting-edge science into evidence-based personalized solutions to help people suffering from pain due to aging, injuries, degenerative and inflammatory conditions. Said Dr. Hagens, “I am most excited to be part of this multi-disciplinary team as we are translating technological advances in aesthetics to provide our patients with individualized treatments options for pain — by leveraging the power of their own unchanged, native adipose cells — all during the same procedure.”

TriCelX’s CEO, Jakes Jordaan, concluded, “With the guidance of our Military Advisory Board, which includes Gen. Lance L. Smith and Brigadier Gen. Mark T. Kimmitt, our team is developing a proprietary biological medical countermeasures cell processing platform — to produce native, non-expanded biologics — to help our warriors facing unique threats such as Acute Radiation Syndrome, Traumatic Brain Injury and battlefield wounds.”

The Baylor Scott & White Sports Therapy & Research Center at The Star – A game-changing sports performance and healthcare destination focused on safety and research in Frisco, Texas at The Star, a sports and entertainment district that is home to the Dallas Cowboys World Headquarters.

Grand Pack Machinery Launches The Newest Pharmatical Filling Machine At ALLPACK INDONESIA EXPO

Grand

Grand Pack Machinery, INC. announces the debut of its latest innovation, the GGS Pharmaceutical Filling Machines, in the 23rd ALLPACK INDONESIA. Designed for the food and pharmaceutical industries, this highly customizable series has streamlined structures and is fitted with casters, which makes it convenient to move them and help customers save costs.

It took us five years to develop the filling machines. Only after dozens of prototype testing and modifications are we ready to debut them in this exhibition. With the features of cost-effectiveness and high filling accuracy, our innovations can meet the production needs of customers in the pharmaceutical and food industries. ” said Bruce Fu, CEO of Grand Pack.

Features:

The GGS series is comprised of four models, namely 118-P5, 240-P5, 240-P10, 240-P15, all of which are constructed in strict accordance with GMP standards. To boost their filling performance, we have mounted pump control panels on them, which makes it possible to real-time monitor the filling speed and increases the level of automation.

Grand’s latest GGS pharmaceutical liquid filling machine

Exploring the Indonesia Market:

As Indonesia’s population expands to 400 million, and the economy becomes one of the fastest-growing in the world, we have established our branch Trustar in this country. As such, by attending this year’s exhibition, we aim to establish our identity in the overseas market, and promote our branch.

In addition, we will also debut our other pharmaceutical filling solutions dedicated to sustainable development at the ALLPack Expo. For example, we are the first to produce a small version of BFS machines that traditionally occupy large footprints. Such upgrade help customers save much space, and reduce waste and cost.

Mark Gaffney Is Appointed CEO of Calluna Pharma | Mark Altmeyer as Independent Chair of the Board

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Chair of the Board. Alongside these appointments, John Montana, who has been acting as the Company’s interim CEO, will return to his role as an Operating Partner at Forbion.

Mark Gaffney brings over 20 years of experience in corporate strategy, business development, and operations in both private and public biotechnology companies, and will lead the team that defines and executes on the corporate strategy, particularly as its lead program is on pace to complete its Phase 1 program later this year.

Prior to Calluna, Mark Gaffney was CEO of Oxular Limited, a company developing novel drug delivery and formulation technologies to treat retinal disorders, where he remains a strategic advisor and member of the Board. Before joining Oxular, he served as Chief Business Officer and later as Chief Operating Officer at Vedere Bio, a company focused on developing next-generation ocular gene therapies, which was acquired by Novartis in late 2020. Gaffney has held corporate development and operational positions at Cyclerion Therapeutics and Ironwood Pharmaceuticals and holds a degree in engineering from the University of Pennsylvania and a Juris Doctor degree from Boston University.

Mark Altmeyer, the newly appointed Independent Chair of the Calluna Board, brings extensive leadership experience, having served on the boards and as an advisor to several pharma and biotech companies. He is currently Chair of AM-Pharma and also serves on the boards of Novaremed, Merz Therapeutics, Aculys, and Alector, all focusing on CNS and neurological treatments. Previously, he was President and CEO of Arvelle Therapeutics, Chief Commercial Officer at Axovant Sciences, and held senior roles at Otsuka America and Bristol-Myers Squibb. Altmeyer holds a BA in Economics from Middlebury College and an MBA from Harvard Business School.

Mark Gaffney, Chief Executive Officer of Calluna Pharma, said: “It has been a rapid and impressive start to our journey as Calluna Pharma following joining forces of Oxitope Pharma and Arxx Therapeutics, two key players in the innate immunology space. I am delighted to join the team at such an exciting stage with Calluna’s lead candidate, CAL101, completing its Phase 1 program this year, and with the other programs in our pipeline demonstrating such promise. I look forward to working with Mark Altmeyer, the other members of our Board and the team as we continue to progress Calluna’s programs to make treatments for fibrotic and inflammatory diseases a reality.”

Mark Altmeyer, Chair of the Board of Calluna Pharma, commented: “It’s a great time to be joining Calluna Pharma’s Board and I look forward to working with Mark Gaffney as we steer company growth and the development of our programs. Working closely with Mark and his leadership team, we will continue to advance our mission to target the root causes of inflammation and fibrosis.”

Marco Boorsma, General Partner, Forbion, outgoing Chair and member of the Board of Calluna Pharma, added: “Calluna’s tailored approach to targeting the root causes of many diseases can be successful where other treatment strategies have fallen short. The Company and its pipeline are poised for success, and I feel confident as we hand over the Chairmanship to Mark Altmeyer who brings vast experience for the next phase of this journey. I would also like to thank John Montana for his leadership and dedication in building the strong foundations for the Company and to welcome Mark Gaffney as incoming CEO.”

Understanding The Risks of Dysphagia And Aspiration

Dysphagia

Dysphagia is the medical term for difficulty swallowing. This condition is more than a simple inconvenience. Dysphagia can cause risks of choking and other health hazards. Although older adults are more likely to suffer from the condition, it can happen to anyone and for multiple reasons. Understanding the risks of this swallowing condition and how to manage it can help those who suffer from dysphagia.

What Is Dysphagia?

Dysphagia is a medical condition in which individuals have trouble pushing foods or liquids from the mouth to the throat. Learning information about dysphagia can help those who have the condition learn to manage it better.

Swallowing difficulties happen for many reasons, including blockages in the throat or esophagus, weakened muscles, and nerve damage. People with conditions like Parkinson’s disease and multiple sclerosis are more likely to develop dysphagia. You may also develop swallowing challenges if you have had a previous stroke. As mentioned, dysphagia is more likely to happen with age because of natural changes in the human body that make swallowing more challenging.

Multiple symptoms can occur with dysphagia, including the following:

Coughing or choking while eating
A sensation of food being stuck in the throat
Painful swallowing
Frequent heartburn

The symptoms can vary among individuals. Some people only have mild symptoms, while others suffer significantly from side effects.

Understanding Aspiration

One of the most dangerous risks of dysphagia is aspiration. Aspiration happens when liquids or food accidentally enter the trachea and head into the lungs instead of the esophagus. When this occurs, individuals can get aspiration pneumonia, a severe and sometimes deadly lung infection. Aspiration pneumonia can be particularly dangerous if you have a weakened immune system because your body may be ill-equipped to fight the infection.

Healthy individuals rarely experience aspiration because their bodies have mechanisms to prevent food and liquids from entering their trachea and lungs. You will start coughing and gagging to avoid the food from “going down the wrong way.”

However, those who are older or in poor health may have weakened muscles and nerve responses that prevent these mechanisms from functioning. You may cough frequently while eating and can even experience silent aspiration. Silent aspiration makes it very challenging to diagnose aspiration pneumonia until it becomes severe.

Who Is More at Risk of Experiencing Aspiration?

While aspiration can happen to anyone, some people are more at risk than others. The following are some of the higher-risk groups:

Older adults
Those with neurological conditions
People with head and neck cancer
People with head or neck injuries
Individuals with GERD

Seek Medical Advice

Aspiration as a result of dysphagia is more than scary or uncomfortable; it can also lead to life-threatening aspiration that can cause pneumonia. Dysphagia is a severe medical condition and should never be ignored. It is essential to understand the underlying cause for proper treatment.

After addressing the underlying cause of the swallowing condition, you can cut the risks of aspiration by eating softer or pureed foods. Thickening additives can thicken liquids and make them easier to swallow. There is also swallowing therapy, which can help individuals increase muscle strength and make swallowing more effective.

It is also essential to sit upright while eating and avoid talking. A slight forward tilt of the head can help with the swallowing mechanisms, preventing choking and aspiration. Seek your doctor if you have the symptoms of dysphagia so you can receive proper treatment.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump’s built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump. Medtronic began investigating this issue upon receiving customer reports of shortened battery life and a comprehensive analysis found that pumps that have been dropped, bumped, or experienced physical impact even once may result in shortened battery life due to damage to internal electrical components.

This electrical issue also causes battery alerts to occur when less battery life remains than the User Guide states. This may result in the pump stopping insulin delivery significantly sooner than usually expected and could lead to health risks like hyperglycemia or diabetic ketoacidosis (DKA), potentially requiring medical intervention. Most recently, Medtronic has received 170 reports of hyperglycemia >400mg/dL and 11 reports of diabetic ketoacidosis from January 2023 to September 2024 in the US potentially related to this issue. The FDA has classified this action as a class I recall.

Medtronic issued an updated notification to customers stating the following:

  • Even a single drop of the pump could result in reduced battery life, either immediately after the drop, or over time, and the issue will continue even after replacing the battery.
  • The pump will still generate battery alerts and alarms, but these alerts and alarms may not be delivered with the usual amount of battery life remaining before the battery must be replaced to avoid the pump stopping insulin delivery. Be prepared to replace the battery as soon as the “Low Battery Pump” alarm sounds.
  • Users should always carry an extra set of new AA lithium or alkaline batteries or fully charged NiMH batteries should they need to replace the battery sooner than expected.
  • Users who notice a significant decrease in battery life from their usual experience, regardless of whether their pump has been dropped, bumped, or has experienced physical impact, should contact their local Medtronic team to determine whether a replacement pump is needed. Customers in the U.S. can call 1-800-378-2292 for 24-hour technical support. Customer outside the U.S. can click on this link to find the number for their local support team.
  • Users are advised to have a back-up therapy available in case it’s needed.

”Medtronic began proactively notifying impacted pump users in July because of the high priority we place on patient safety and understand the important role of pumps in the care and management of diabetes,” said Robert Vigersky, MD, Chief Medical Officer, Medtronic Diabetes. “Our team is here 24 hours a day, 7 days a week to help if you experience battery depletion or any other issue with your pump. Patient safety is our priority, as is continuity of therapy, which is why we made the decision to voluntarily notify patients and will replace pumps when needed.”

The original notification and the updated notification are available on the Medtronic Diabetes website.

Syncona: Resolution Therapeutics Raises £63.5 Million in Series B Financing | Appoints New Chair

Syncona Ltd, (“Syncona” or the “Company”), a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science, today announces that it has committed £63.5 million in a Series B financing of Resolution Therapeutics (“Resolution”), a portfolio company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases. Syncona has invested an initial tranche of £22.0 million1, with investment of the full Series B commitment tranched upon the completion of key milestones.

Alongside this investment, Resolution has appointed Paul Sekhri as Chair of Resolution’s Board of Directors. From a career in life sciences spanning over 35 years, Paul brings a wealth of relevant industry experience to Resolution that will support its future growth, with particular expertise in drug development, business development and delivering successful financing strategies. He is currently President and CEO of vTv Therapeutics and was previously President and CEO of eGenesis and Lycera Corp. Paul has significant senior management, executive and non-executive experience, having worked across biotechnology and large corporate pharmaceutical companies, as well as private equity and venture capital firms.

Launched by Syncona in 2020, Resolution is targeting end-stage liver disease (ESLD), a severe form of liver failure, where a lack of effective therapeutic options means that patients often require liver transplantation and often die as a consequence of the disease. To date, the company has published proof-of-principle data from the academic MATCH II study on the use of macrophage cell therapy in ESLD. Based on the strength of this data, Resolution is now focused on advancing its lead candidate, RTX001, an enhanced, next-generation macrophage cell therapy with first-in-class potential for ESLD.

Use of proceeds from the Series B financing will support the clinical entry and development of RTX001, with a Phase I/II trial expected to start in Q4 CY2024. Following this financing, Resolution Therapeutics is funded to deliver data from this trial, anticipated in CY2026, a key value inflection point with the potential to drive significant NAV growth for Syncona. Proceeds will also be used to develop the company’s manufacturing platform, expand the pre-clinical pipeline, and further strengthen the management team, following several key recent appointments, including Dr Amir Hefni as CEO, Simon Ramsden as CFO and Dr Clifford A. Brass as CMO.

The Series B financing brings the total amount raised by Resolution Therapeutics to £101.4 million[3]. Following the drawdown of the full Series B financing, Syncona’s ownership stake in Resolution will be 82.6 per cent. Including the drawdown of the first tranche of investment of £22.0 million, Syncona’s holding value of Resolution is now £63.6 million. Following the financing, Syncona Investment Partner Gonzalo Garcia has joined Resolution’s Board of Directors, joining Managing Partner Edward Hodgkin.

Edward Hodgkin, Managing Partner of Syncona Investment Management Limited and Non-Executive Director of Resolution, said:

“The data that Resolution has generated to date in this emerging area of medicine is encouraging and, in our view, demonstrates the potential that macrophages have in treating end-stage liver disease. This is a potential first-in-class product being developed for a disease where patients have no effective therapeutic options and typically face a liver transplant or further deterioration of their condition, which is often fatal. We are delighted to continue to support Resolution with our commitment to its Series B financing, in-line with Syncona’s focus on allocating capital to clinical-stage assets and assets approaching clinical entry. We are also very pleased to welcome to Resolution Paul Sekhri, who brings a demonstrable track record in supporting companies through the development cycle and will act as a valuable sounding board for the company’s growing executive team.”

Amir Hefni, Chief Executive Officer of Resolution, said: “As we prepare to advance RTX001, our lead investigational macrophage therapy with first-in-class potential for the treatment of end-stage liver disease, into the clinic this year, we are grateful for Syncona’s continued support. In addition, we are pleased to welcome Paul Sekhri to our Board of Directors. Paul brings a wealth of experience leading top-tier companies to develop breakthrough medicines, including novel treatments for patients with autoimmune disease. The team and I look forward to working with Paul to bring novel macrophage therapies, like RTX001, to patients in need.”

Paul Sekhri, Chair of Resolution, said: “I am delighted to join Resolution at such an exciting time as it prepares to enter the clinic with RTX001 and expand pipeline efforts into new indications where significant unmet patient need exists. I look forward to collaborating with Amir, the entire Resolution team and supporting the company as it expands its leadership in macrophage therapy.”


[1] This investment includes a £12.0 million convertible loan note provided by Syncona in March 2024, which converted to the Series B financing on successful closure of the round.

2 This holding value incorporates value accrued through interest from the convertible loan note and through its conversion to the Series B financing.

3 Assuming full investment of the Series B commitment, which is tranched upon the completion of key milestones.